Observational study of the sociodemographic characteristics of patients infected with HIV B subtype versus HIV non-B subtype and having recently started their first course of antiretroviral treatment. FRESH-PEF1252-en Isabelle COHEN-CODAR Observational study of the sociodemographic characteristics of patients infected with HIV B subtype versus HIV non-B subtype and having recently started their first course of antiretroviral treatment. BINOME FRESH-PEF1252-en 1252 FRESH-PEF1252 Isabelle COHEN-CODAR ABBOTT FRANCE Epidemiology France Portal (PEF) ABBOTT FRANCE null anti-retroviral drug treatment (ARV) viral subtype Protease inhibitors (PI) non-nucleoside reverse transcriptase inhibitors (NNRTI) HIV Infectious disease medicine Socio-demographic and economic determinants: Employment Socio-demographic and economic determinants Healthcare system determinants: Use of care Healthcare system determinants Describe and compare the socio-demographic characteristics of patients infected with an HIV-1 of subtype B (group 1) compared to non-B (group 2) treated with a first anti-retroviral drug treatment. Compare according to the HIV subtype the stage of the disease (clinical, viro-immunology, co-morbidities) at the time treatment is initiated, compare between the 2 groups (B and non-B) the conditions for taking the treatment and the perception by the patient of the therapy and of its effects. Identification of any correlation between these latter parameters and the change in the disease between the initiation and the first line ARV and the inclusion in the cohort: - change in the viral load (VL) according to the ARV treatment (PI, NNRTI) and of the HIV subtype (B or non-B), of the CD4, - any occurrence of clinical events, - any changes in treatments and reasons. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Age > 18 years, obtaining of written consent for the collection of this personal data, patient infected by the HIV-1 virus, patient coming to consult for the first or second routine follow-up visit (i.e. 1 to 4 months) after the initiation of the ARV treatment, genotype available when the treatment is initiated. Clinical data Participant-reported health data Biological data Health event/morbidity Health care consumption and services Quality of life/health perception One-time cross-sectional study Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Observational Study Observational Study 304 Completed study To be defined Access on specific project only